Beyond 600 Days! Bao Pharma Helps Set New Asian Record in Xenogeneic Kidney Transplantation

Source: Bao Pharma

A gene-edited pig kidney has been beating the odds inside a recipient monkey for more than 600 days — a milestone that researchers say marks a major breakthrough in China's push to make xenotransplantation a viable solution to the world's chronic organ shortage.

The recipient primate remains in good health with stable kidney function, according to a joint update from Tongji Hospital at Huazhong University of Science and Technology, Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma), and Zhongke Aoge, the collaborators behind the project. The result sets a new Asian record for the longest survival of a non-human primate following a xenogeneic kidney transplant.

Tackling the Organ Gap

The gap between the number of patients with end-stage kidney disease and the supply of donor organs continues to widen, making it one of the most pressing challenges in global transplant medicine. Xenotransplantation — particularly the use of gene-edited pig organs — has emerged as one of the most promising avenues for closing that gap.

But the path is fraught with immunological hurdles: hyperacute rejection, antibody-mediated rejection, complement activation, coagulation abnormalities, and the difficulty of maintaining long-term immune tolerance. Whether a transplanted organ can survive and function over an extended period remains the core benchmark for judging how mature the technology has become.

Bao Pharma entered the picture as a key contributor to the project's immunomodulation strategy. Drawing on its R&D strengths in recombinant proteins, bioenzymes, and immunomodulatory drugs, the company supplied several critical pharmaceutical agents that supported the long-term survival of the recipient monkey. The animal's survival beyond 600 days with stable graft function, the team said, validates the collaborative group's integrated capabilities across donor-pig construction, surgical technique, perioperative management, immune regulation, and long-term monitoring.

A Coordinated Push

The project brought together institutions with complementary expertise, each tackling a different piece of the xenotransplantation puzzle:

Tongji Hospital, Huazhong University of Science and Technology contributed its deep experience in clinical and translational organ-transplant research, providing essential medical know-how and technical support.

Zhongke Aoge, which has long focused on developing gene-edited donor pigs, supplied the critical donor resources and technology platform.

Bao Pharma leveraged its capabilities in recombinant proteins, bioenzymes, and immunomodulatory drug development to support the exploration and innovation of immunointervention strategies for xenotransplantation.

The collaboration reflects what the partners describe as an innovation model driven by clinical need, underpinned by core technologies, and executed through multidisciplinary teamwork — a framework they say lays a firmer foundation for moving xenotransplantation from basic research toward clinical translation in China.

More Than a Number

The 600-day mark is significant not just as a measure of time, but as evidence that a transplanted pig kidney can maintain stable function over an extended follow-up period. The result suggests that with the right combination of donor-pig gene-editing strategies, precise immune regulation, and rigorous perioperative and long-term management, xenogeneic kidney transplants can achieve increasingly durable organ function.

For the field, long-term survival data are invaluable. They allow researchers to evaluate graft stability and to probe critical scientific questions — chronic rejection, antibody responses, inflammatory injury, coagulation regulation, and immune reconstitution — that will inform the design of future clinical studies.

The Road Ahead

Xenotransplantation is a highly complex systems-engineering challenge that requires coordinated progress across donor animals, gene editing, immunosuppressive drugs, transplant surgery, infection control, long-term monitoring, and ethical oversight. From the early days of surviving past 100 days to the current 600-day benchmark, China's xenotransplantation research has been steadily breaking records, accumulating evidence, and advancing toward a more mature stage of development.

For Bao Pharma, the milestone provides important evidence supporting the value of its immunomodulatory drugs in xenotransplantation settings. Looking ahead, the company said it will continue to draw on its expertise in recombinant proteins and immunomodulatory therapies, working with partner teams to investigate the long-term safety, efficacy, and translatability of xenotransplantation — and to push the relevant technologies closer to the day when they can offer real hope to the millions of patients worldwide living with end-stage organ failure.

About Bao Pharma
Bao Pharma is an innovative biotechnology company that uses synthetic biology technology to develop and produce recombinant biopharmaceuticals that are difficult to express through conventional genetic engineering, aiming to meet broad clinical needs. The company focuses on replacing traditional biochemical-extracted drugs and upgrading existing therapies, building a diversified product pipeline with differentiated strengths spanning large-volume subcutaneous administration, antibody-mediated autoimmune diseases, assisted reproduction, and the replacement of traditional biochemical products with recombinant biopharmaceuticals. With leading chassis-cell construction capabilities, a stable commercialized production system, and an experienced R&D team, Bao Pharma is committed to becoming a global pioneer in the recombinant biopharmaceutical field.

Forward-Looking Statements: This press release may contain forward-looking statements based on management's current expectations, assumptions, and forecasts. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially. Bao Pharma undertakes no obligation to update any forward-looking statements unless required by law. The information herein is for reference only and does not constitute investment advice or an offer to purchase securities.